A Retrospective, Non-interventional Study to Evaluate EGFR-Tyrosine Kinase Inhibitor Retreatment in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC Who Previously Treated With EGFR-TKI as First-line Therapy and Chemotherapy as Second-line Therapy – SEQUENCE Study

by lowes1 on October 7, 2013

Condition:   Locally Advanced or Metastatic EGFR Mutated NSCLC.
Intervention:  
Sponsors:   AstraZeneca;   AstraZeneca
Not yet recruiting – verified September 2013

View full post on ClinicalTrials.gov: “Lung Neoplasms” | updated in the last 30 days

Leave a Comment

Previous post:

Next post: